Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance.

K BerencsiA SamiM S AliK MarinierN DeltourS Perez-GutthannL PedersenP RijnbeekJ Van der LeiF LapiM SimonettiC ReyesM C J M SturkenboomDaniel Prieto Alhambra

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2019)

Our study demonstrates a substantial impact of the regulatory action to restrict use of SR in Europe: SR utilisation overall decreased strongly. The proportion of patients fulfilling the restricted indications, without contraindications, increased after the proposed RMMs.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
transcription factor
peritoneal dialysis
emergency department
patient reported